|
It was reported that a patient underwent a transcarotid artery revascularization (tcar) procedure with implantation of a cguard prime carotid stent 135 and subsequently experienced a neurological event.The physician confirmed a stroke through physical neurological examination findings, computed tomography angiography (cta), and magnetic resonance imaging (mri) performed the day following the procedure.Additional information was received on (b)(6), 2026 indicating that according to the physician, the patient's neurological symptoms returned to baseline during the subsequent week.
|
|
This mdr is being submitted retrospectively as part of capa-us-002-26, identified during a retrospective review conducted under the capa.It was reported that the device was utilized during a transcarotid artery revascularization (tcar) procedure.Tcar is not an approved indication for use of the cguard prime carotid stent system 135cm in the united states and therefore represents off-label use of the device.Based on the information received and the results of the investigation, no device malfunction, manufacturing deficiency, or device mechanism-related issue was identified.A definitive root cause could not be determined.The reported event is a known potential adverse event associated with carotid artery stenting and may also be influenced by patient, lesion, procedural, or other clinical factors.Complaint trending and post-market surveillance activities are performed on an ongoing basis.Appropriate actions will be evaluated and implemented should an increase in similar events be identified.The cguard prime 135 cm delivery system instructions for use (ifu), include the following warning: "the stent systems may cause thrombus migration from the implant site along the arterial lumen and may produce distal embolization.".
|